Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Pemvidutide Promise | Explore pemvidutide's potential in MASH and obesity treatment, with unprecedented liver fat reduction and significant weight loss results |
Expanding Horizons | Delve into Altimmune's strategic expansion of pemvidutide applications to include alcohol use disorder and alcoholic liver disease |
Clinical Milestones | Anticipate key clinical trial outcomes, including the Phase 2b IMPACT trial for MASH, with top-line data expected in Q2 2025 |
Market Potential | Analyst price targets range from $12 to $28, with projected peak U.S. sales exceeding $2.5 billion for MASH indication alone |
Metrics to compare | ALT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.3x | −2.1x | −0.6x | |
PEG Ratio | −0.24 | 0.31 | 0.00 | |
Price/Book | 3.7x | 2.4x | 2.6x | |
Price / LTM Sales | 34,751.7x | 44.8x | 3.4x | |
Upside (Analyst Target) | 257.1% | 155.8% | 44.9% | |
Fair Value Upside | Unlock | 6.3% | 6.3% | Unlock |